6 Ways Biotech Companies Can Extend Their Cash Runway During Difficult Economic Times
24 April, 2023Six best practices biotech companies can employ to extend their cash runway during difficult economic times
Six best practices biotech companies can employ to extend their cash runway during difficult economic times
From AI to telemedicine, how emerging technologies are poised to transform the healthcare industry
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Gene Editing have become hot topics in the biotechnology industry due to their tremendous potential for revolutionizing medicine, agriculture, and biotechnology.
The biotech industry is one of the most promising areas for investment, with numerous opportunities for growth and innovation.
A biotech roll-up, also known as a merger or acquisition, is a business strategy that involves the consolidation of multiple biotech companies into a single entity.
Life Sciences deal making is a crowded but attractive field. Research firm Bain and Company reports that there are some 3425 biotech businesses in the US at the start of 2023
In the fast-paced and highly competitive world of life sciences, intellectual property management is a critical component of deal making.
Strict security policies not only protect customers, it instills trust in your company’s brand in the marketplace.
The Biotech sector is experiencing a tough slog. Share values are down and venture capital funds are growing scarce, even for formerly white-hot categories like Oncology drugs. Industry analysts are calling it a “Biotech Winter.”
Cybersecurity is essential for global dealmakers. Check out our webinar to learn the successes and challenges of doing deals remotely.